Endoskeletal nanodrops for x-ray acoustic dosimetry

用于 X 射线声剂量测定的内骨骼纳米滴

• 批准号: 10429759
• 负责人: Mark Andrew Borden
• 金额: $ 20.04万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-07-15 至 2024-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10429759
• 关键词: 3-Dimensional; Acoustics; Address; Algorithms; Anatomy; Body Weight decreased; Cancer Patient; Clinical; Clinical Trials; Contrast Media; Contrast Sensitivity; Data; Detection; Devices; Dose; Drops; Dyes; Ensure; Fatty acid glycerol esters; Fluorocarbons; Formulation; Future; Geometry; Goals; Heating; Hydrocarbons; Image; Ions; Lead; Linear Accelerator Radiotherapy Systems; Liquid substance; Measurement; Measures; Medical; Metals; Methods; Microbubbles; Noise; Normal tissue morphology; Patient-Focused Outcomes; Patients; Phase; Photons; Physiologic pulse; Preclinical Testing; Publications; Radiation; Radiation Dose Unit; Radiation therapy; Radiometry; Reproducibility; Roentgen Rays; Signal Transduction; Skeleton; Solid; Structure; System; Techniques; Technology; Time; Tissues; Toxic effect; Treatment outcome; Tumor Volume; Ultrasonography; United States; Work; X-Ray Computed Tomography; absorption; base; cancer therapy; clinical translation; commercialization; contrast enhanced; design; dosimetry; experimental study; imaging agent; improved; improved outcome; in vivo; interest; melting; novel; particle; radiation delivery; rapid growth; reconstruction; response; side effect; simulation; skeletal; treatment planning; tumor; ultrasound; vapor; vaporization

PROJECT SUMMARY More than half of all cancer patients in the United States receive Radiation Therapy (RT) as a part of their cancer treatment (>500,000 patients per year). Cancer patients typically receive a highly targeted dose of radiation over the course of days or weeks. Each patient will typically receive 25-40 daily treatments. Treatment outcome is dependent on accurate delivery of radiation. All RT patient treatment plans are based on a planning `simulation' CT scan, acquired days or weeks before the start of treatment. However, due to weight loss or tumor shrinkage in the time between simulation and treatment, anatomical changes may lead to healthy tissues being irradiated. Side effects of irradiating healthy tissue can be severe. Adaptive optimizing has chance . However, the implementation of ART is severely limited by the lack of a real-time device that can accurately measure the delivered radiation distribution within the patient. Currently no system exists which is capable of measuring the radiation dose distribution within the patient. RT (ART) – re- the radiation distribution based on the patient's daily anatomy in order to maintain the plan quality – been proposed as a means to deliver more radiation with reduced normal tissue damage; increasing the of a cure, with fewer side effects This project will address this need by developing the first contrast agent for imaging radiation therapy. Our approach will employ the x-ray acoustic (XA) effect, which is analogous to the “photoacoustic effect”, a physical phenomenon whereby acoustic waves are generated by the absorption of heat energy from a pulsed photon beam. In XA Computed Tomography (XACT), the photon beam is high-energy x-ray radiation generated by a medical linear accelerator (LINAC) used in clinical radiation therapy. Novel XA contrast agents are needed to improve XACT imaging and are essential to our concept of XACT dosimetry. Toward this end, we recently invented vaporizable endoskeletal drops (VEDs) comprising a liquid fluorocarbon droplet with a solid hydrocarbon “skeleton”. We discovered that the liquid fluorocarbon droplet vaporizes upon heating and melting of the hydrocarbon solid. The drop-to-bubble expansion emits an acoustic wave that can be imaged with XACT, and the resulting microbubble is echogenic for ultrasound imaging. This project will develop the VED technology into a novel radiation therapy contrast agent for XACT by 1) Formulation of VEDs comprising high-z metal ions within the hydrocarbon skeletal phase to absorb x-rays and stimulate vaporization; and 2) Measurement of the XA effect of high-z VEDs. Completing these aims will enable future commercialization, in vivo preclinical testing, and clinical translation.

项目摘要 美国的所有癌症患者中有一半以上接受放射疗法（RT）作为其一部分 癌症治疗（每年> 500,000名患者）。癌症患者通常会接受高度靶向剂量的 几天或几周的辐射。每个患者通常会接受25-40例每日治疗。 治疗结果取决于准确的辐射输送。所有RT患者治疗计划均基于 计划“模拟” CT扫描，在开始治疗开始前几天或几周内获得。但是，由于重量 在模拟和治疗之间的时间内损失或肿瘤收缩，解剖学变化可能导致健康 组织被照射。辐照健康组织的副作用可能很严重。自适应 优化 有 机会。但是，艺术的实施受到缺乏的严重限制 一个可以准确测量患者中输送的辐射分布的实时设备。 不存在能够测量患者内部辐射剂量分布的系统。 RT（艺术） - 重新 基于患者每日解剖结构的辐射分布以保持计划质量 - 被提出是一种用来减少正常组织损伤的更多辐射的手段；增加 治愈的副作用较少 该项目将通过开发成像辐射疗法的第一个对比剂来满足这一需求。我们的 方法将采用X射线声学（XA）效应，该效应类似于“光声效应”，一种物理 现象是通过从脉冲照片中吸收热能来产生声波的现象 光束。在XA计算机断层扫描（XACT）中，光子束是由A产生的高能量X射线辐射 用于临床放射疗法的医疗线性加速器（LINAC）。需要新颖的XA对比剂 改善XACT成像，对于我们的XACT剂量测定概念至关重要。为此，我们 最近发明了可蒸发的内骨滴剂（VEDS），完成了液态碳液滴的固体液滴 碳氢化合物“骨骼”。我们发现液态碳液滴液滴在加热和熔化后蒸发 碳氢化合物固体。跌至淡淡的膨胀发出的声波可以成像 XACT，所产生的微泡是超声成像的回声。该项目将开发VED 通过1）配方符合VED的高Z的技术，用于XACT的新型放射疗法对比剂 烃骨骼相中的金属离子吸收X射线并刺激分散体；和2） 测量高Z VED的XA效应。完成这些目标将使以后的商业化能够 体内临床前测试和临床翻译。